Search results

771 results

Sorted by Date . Sort by Relevance

In development Remove In development filter
Proposed Remove Proposed filter
Technology appraisal guidance Remove Technology appraisal guidance filter
Interventional procedures guidance Remove Interventional procedures guidance filter
NICE guidelines Remove NICE guidelines filter
Clinical guidelines Remove Clinical guidelines filter
Social care guidelines Remove Social care guidelines filter

Entinostat for treating hormone receptor-positive breast cancer after hormonal therapy ID1260

In development [GID-TA10309] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Ibrutinib for untreated mantle cell lymphoma (ID1221)

In development [GID-TA10185] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
KTE-C19 for previously treated B-precursor acute lymphoblastic leukaemia in people aged 2 to 21 ID1336

In development [GID-TA10316] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Lacosamide for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [ID1687]

In development [GID-TA10664] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Lung transplantation with ex-vivo perfusion

In development [GID-IP1046] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Stye: antimicrobial prescribing

In development [GID-NG10167] Expected publication date: TBC

Type

Antimicrobial prescribing guideline

Status

In development
Blepharitis: antimicrobial prescribing

In development [GID-NG10168] Expected publication date: TBC

Type

Antimicrobial prescribing guideline

Status

In development
Durvalumab for untreated PD-L1 positive metastatic urothelial bladder cancer ID1169

In development [GID-TA10324] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Durvalumab with tremelimumab for untreated PD-L1-positive urothelial bladder cancer ID1335

In development [GID-TA10315] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Olaparib for maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after initial platinum-based chemotherapy [ID1518]

In development [GID-TA10504] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Bupivacaine–meloxicam for treating postoperative pain [ID2728]

Proposed [GID-TA10716] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Mepolizumab for treating hypereosinophilic syndrome [ID3749]

Proposed [GID-TA10755] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Microwave ablation for treating primary lung cancer and metastases in the lung

In development [GID-IPG10181] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Stereotactic radiosurgery for trigeminal neuralgia using the gamma knife

In development [GID-IPG10179] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Intramedullary distraction for lower limb lengthening

In development [GID-IPG10180] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Pembrolizumab with chemotherapy for untreated metastatic urothelial cancer ID1545

In development [GID-TA10418] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Nivolumab with ipilimumab for untreated unresectable metastatic oesophageal squamous cell carcinoma [ID1629]

In development [GID-TA10576] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Epilepsies in adults: diagnosis and management update (Please see Epilepsies in children, young people and adults)

In development [GID-NG10110] Expected publication date: TBC

Type

NICE guideline

Status

In development
Avelumab for treating gastric or gastro-oesophageal junction cancer after 2 therapies ID1289

In development [GID-TA10210] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women ID1401

In development [GID-TA10326] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Dabrafenib with trametinib for treating advanced, metastatic BRAF V600E mutation-positive non-small-cell lung cancer [ID929]

In development [GID-TA10121] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Erdafitinib for treating metastatic or unresectable FGFR-positive urothelial cancer [ID1333]

In development [GID-TA10252] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Durvalumab for treating recurrent or metastatic squamous cell head and neck cancer after platinum-based chemotherapy [ID1231]

In development [GID-TA10473] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Ibrutinib for treating relapsed or refractory follicular lymphoma [1251]

In development [GID-TA10223] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Cutting blocks for total knee arthroplasty

In development [GID-IP1112] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Apalutamide with abiraterone acetate and prednisone for treating metastatic hormone-relapsed prostate cancer [ID1480]

In development [GID-TA10465] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pegargiminase with pemetrexed and cisplatin for untreated advanced malignant pleural mesothelioma [ID1575]

In development [GID-TA10486] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Nivolumab with ipilimumab for treating squamous cell carcinoma of the head and neck ID1355

In development [GID-TA10321] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Mirvetuximab soravtansine for previously treated platinum-resistant FR-alpha positive ovarian cancer [ID1527]

In development [GID-TA10483] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Venetoclax with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma ID1565

In development [GID-TA10502] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Depatuxizumab mafodotin in combination for untreated EGFR-amplified glioblastoma ID1466

In development [GID-TA10355] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Nintedanib for previously treated metastatic colorectal cancer [ID1030]

In development [GID-TA10138] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Nivolumab for treating relapsed or refractory diffuse large B-cell lymphoma [ID986]

In development [GID-TA10140] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma after autologous stem cell transplant [ID1103]

In development [GID-TA10144] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
NGR-TNF for previously treated advanced malignant pleural mesothelioma (ID655)

In development [GID-TA10183] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Nivolumab for treating recurrent glioblastoma [ID998]

In development [GID-TA10126] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Multiple sclerosis (primary-progressive) - fingolimod [ID62]

In development [GID-TAG221] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pelareorep for treating recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer [ID1099]

In development [GID-TA10688] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
NBTXR-3 for treating soft tissue sarcoma [ID1050]

In development [GID-TA10226] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
L-glutamine for preventing painful crises in sickle cell disease in people aged 5 years and over [ID1523]

In development [GID-TA10452] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Workplace health for employees with disabilities and long-term conditions

In development [GID-PHG58] Expected publication date: TBC

Type

NICE guideline

Status

In development
Veliparib with carboplatin and paclitaxel for untreated non-squamous non-small-cell lung cancer [ID1277]

In development [GID-TA10248] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Nivolumab monotherapy for non-small-cell lung cancer [ID1088]

In development [GID-TA10148] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Nivolumab with radiation therapy for untreated glioblastoma ID1562

In development [GID-TA10443] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Nivolumab in combination with platinum-doublet chemotherapy for untreated non-small-cell lung cancer (ID1135)

In development [GID-TA10233] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Brentuximab vedotin for untreated advanced Hodgkin lymphoma [1258]

In development [GID-TA10224] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Atezolizumab with cobimetinib for untreated BRAF wild-type metastatic melanoma ID1470

In development [GID-TA10354] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Crizotinib for treating metastatic c-MET exon 14-positive non-small-cell lung cancer [ID1472]

In development [GID-TA10625] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Ublituximab with ibrutinib for previously treated chronic lymphocytic leukaemia [ID1476]

In development [GID-TA10447] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Eculizumab for treating refractory myasthenia gravis [ID1064]

In development [GID-TA10176] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development